Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  EurekAlert

Philadelphia, January 15, 2019 - A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology ...

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

India- Retinal Vein Occlusion Market 2019 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2023 Available at Market Research Future  MENAFN.COM

(MENAFN - GetNews) Market Research Future has starting late imparted another examination to its wide research portfolio, which is titled as 'Retinal Vein ...

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-m | OPTH  Dove Medical Press

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-month follow-up study.

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 2.9% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. with ticker code (REGN) have now 22 analysts in total covering the stock. The consensus rating is 'Buy'. The target price.

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

SCORE2 subanalysis: Visual gains made after treatment switch  Healio

WAIKOLOA, Hawaii — Visual acuity letter score and central subfield thickness both improved in eyes treated with aflibercept after a poor response to ...

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and Forecast to 2023 |  Medgadget

Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein ...

Retinal Vein Occlusion Therapeutics – Growing Popularity and Emerging Trends in the Market 2019 – Page 31721  TheTokenClock

HTF MI released a new market study on Global Retinal Vein Occlusion Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread ...

CIBC Private Wealth Group LLC Has $2.02 Million Position in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

CIBC Private Wealth Group LLC decreased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 20.6% in the fourth quarter, according to the ...

Global Retinal Vein Occlusion Therapeutics Market 2018- Acucela Inc, Addmedica SAS  Industry News Blog

“Retinal Vein Occlusion Therapeutics Market report highlights the current and future status of market and regional level analysis with the help of industry trends ...

Avastin as effective as Eylea for treating central retinal vein occlusion  EurekAlert

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN is likely to beat expectations when it releases fourth-quarter and full year 2018 results on Feb 6, before the.

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Cystoids Macular Edema Market Segmented By Diagnosis, Therapy And Geography During 2017-2025  openPR

MarketResearchReports.Biz is providing you Retail Market Research report of "Cystoid Macular Edema Market - Global Industry Trend Analysis 2012 to 2017 ...

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

Regeneron Pharmaceuticals (REGN) Stock Rating Upgraded by Zacks Investment Research  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Research Analysts Offer Predictions for Regeneron Pharmaceuticals Inc’s Q2 2019 Earnings (REGN)  Fairfield Current

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Analysts at Jefferies Financial Group issued their Q2 2019 earnings per share estimates for Regeneron ...

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

Global Retinal Vein Occlusion Therapeutics Market Overview 2019-2025 by Manufacturers: Sanofi Aventis, Valeant Pharmaceuticals, Allergan  Industry News Source

Global Retinal Vein Occlusion Therapeutics Market Research Report evaluate worldwide market product categories, regions, with sales, Retinal Vein Occlusion ...

Regeneron Pharmaceuticals (REGN) Stock Rating Reaffirmed by Cowen  Fairfield Current

Cowen reaffirmed their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Monday, January 7th. Cowen ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Ophthalmic Suspension Market Expected To Witness A Sustainable Growth Over 2025 By Novartis, ALLERGAN, Pfizer, Merck, Valeant Pharmaceuticals, Bayer, Genentech, Falcon Group, Ciron Drugs And Pharmaceuticals Private Limited And others  Wise Awareness

Global Ophthalmic Suspension Market Study incorporates the showcase modules ' improvement conditions and definition. The worldwide advertise is classified ...

Case Report Highlights Acute Central Retinal Vein Occlusion in Scleroderma Patient  Scleroderma News

Researchers in Saudi Arabia at King Fahd Hospital of the University and the University of Dammam reported a case of a male patient with scleroderma who was ...

Regeneron Pharmaceuticals (REGN) Raised to Buy at Guggenheim  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities research analysts at Guggenheim from a “neutral” rating to a “buy” rating in a research ...

CRYSTAL study shows good results of personalized anti-VEGF treatment regimen in CRVO  Healio

Two-year results of the CRYSTAL study show that an as-needed medication regimen with frequent monitoring can reduce the number of anti-VEGF injections ...

Regeneron Pharmaceuticals (REGN) Scheduled to Post Quarterly Earnings on Wednesday  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) will be issuing its quarterly earnings data before the market opens on Wednesday, February 6th. Analysts expect ...

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium  PRNewswire

TARRYTOWN, N.Y., Feb. 9, 2019 /PRNewswire/ -- Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious.

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Biotechnology Companies See Growth in Optic Treatment Sectors  PRNewswire

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- The vast number of people in need of medical treatment has grown tremendously over the years. Some cases are a ...

Cheap Avastin as effective as Eylea in CRVO  European Biotechnology

A study conducted by an NIH institute proves Roche's Avastin is as effective as Regeneron's Eylea, a drug that costs 30 times more than Roche's antibody.

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment  Bel Marra Health

Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where the main vein of the retina has become blocked. Much like other organs of ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Laser Speckle Flowgraphy Can Assist in CRVO Prognosis  Medscape

Laser speckle flowgraphy may offer a noninvasive method of assessing ocular blood flow in patients with central retinal vein occlusion (CRVO), according to a ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

2 Rare, But Real, Side Effects Everyone Should Know Before Getting Fillers  NewBeauty Magazine

Doctors explain two rare, but serious, side effects to dermal fillers: overfill and occlusion.

VIDEO: SCORE2 and LEAVO trials underway to compare CRVO treatments  Healio

KOLOA, Hawaii ― At Hawaiian Eye 2017, Michael S. Ip, MD, updates colleagues on the U.S.-based SCORE2 trial and the U.K.-based LEAVO trial, both of which ...

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing ...

Surgical robot successfully removes blood clot in patient with retinal vein occlusion  Healio

Blockage from a blood clot causing retinal vein occlusion in a patient was for the first time removed with the help of a surgical robot at the University Hospitals ...

Ocular Diagnostic Agents Market to Register a Stout Growth by End 2026 - Press Release  Digital Journal

This press release was orginally distributed by SBWire. Albany, NY -- (SBWIRE) -- 02/15/2019 -- Eye is the most accessible organ in the human body. Due to this ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Retinal Vein Occlusion Market 2019 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2023 Available at Market Research Future - Press Release  Digital Journal

"Retinal Vein Occlusion Market"Market Research Future has starting late imparted another examination to its wide research portfolio, which is titled as “Retinal ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Risk Factors for Retinal Vein Occlusion  Medscape (subscription)

Is there a link between traditional risk factors for vascular disease and retinal vein occlusion?

Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019  PRNewswire

Combination of BRAFTOVI, MEKTOVI and ERBITUX® (cetuximab) demonstrated 15.3 months median overall survival in safety lead-in of the Phase 3 BEACON ...

Intravitreal corticosteroid implant vs intravitreal ranibizumab for th | DDDT  Dove Medical Press

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials Qingquan Wei,1 ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

New gene therapy for vision loss proven safe in humans  Medical Xpress

In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Switching to Aflibercept Demonstrates Improvement in VA, CST for Poor Responders to Bevacizumab in SCORE2  MD Magazine

Those who were switched to aflibercept improved 9 letters of VA, and 110 µm in CST from months 6 to 12.

Dexamethasone implant for macular edema improves VA, CRT  Healio

Patients with macular edema who received a dexamethasone intravitreal implant experienced significantly improved best corrected visual acuity and central ...

Altris.AI – The New Era of Retinal Diagnosis is Coming  Business Wire

Altris.AI (Altris, Inc) announced it has signed an agreement with a South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co., Ltd.

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

High Blood Pressure, High Cholesterol May Be Associated With Retinal Vascular Disease  Science Daily (press release)

High blood pressure and high cholesterol levels appear to be risk factors for retinal vein occlusion, a condition that causes vision loss, according to a new article.

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  Business Wire

Genentech's investigational Port Delivery System with ranibizumab (PDS) is a small, refillable device, slightly longer than a grain of rice, surgically implanted in ...

Roche reports very strong results in 2018  GlobeNewswire

Basel, 31 January 2019. Group sales increase 7% [1] at constant exchange rates and in Swiss francs. Pharmaceuticals Division sales up 7%, driven mainly by ...

Bevacizumab, Ranibizumab Biosimilars Proven Effective, Safe for Retina Diseases  MD Magazine

The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.

Oculocare's Alleye® Receives FDA 510(k) Clearance for Monitoring Eyesight in AMD  PR Newswire

ZURICH, July 9, 2018 /PRNewswire/ -- Oculocare medical Inc., a Swiss technology company, announces today the FDA 510(k) clearance of Alleye®, a mobile ...

Similar Efficacy for Key Anti-VEGF Agents in Macular Edema  Medscape

The SCORE2 trial shows that bevacizumab and aflibercept may produce similar short-term outcomes. Here is a closer look at its results.

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron  Seeking Alpha

Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.

Ophthalmic Suspension Market 2023: Projection of Each Major Segment, Drugs and Treatment over the Forecast Period, focusing on top key Vendors like Novartis AG, ALLERGAN, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Falcon Group, Valeant an  openPR

An expert on premium research reports, Market Research Future has added a report titled "Global Ophthalmic Suspension Market 2023" to its offering.

Novartis nAMD Treatment Brolucizumab Shows Superiority Against Regeneron's Eylea at Two Years  BioSpace

With *fresh* two-year data in hand, Novartis remains focused on seeking regulatory approval for brolucizumab, an ophthalmology drug for the treatment of ...

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

Evaluation of contrast sensitivity and other visual function outcomes | OPTH  Dove Medical Press

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ...

Revealing the retina: Graphene corneal contact lens provides robust, irritation-free topographic electroretinography  Phys.org

Our vision can be damaged or lost by damage to the retina—a sensory membrane lining the back of the eye that senses light, converting the image formed into ...

The eye jab that can banish blind spots  Daily Mail

Clive Woodington had Central Retinal Vein Occlusion (CRVO), a distressing condition that can lead to blindness in the affected eye.

Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies  Nasdaq

Aerie Pharmaceuticals, Inc. AERI announced that the FDA has reviewed the Investigational New Drug (IND) application for AR-1105 (dexamethasone ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

Increase in choroidal thickness seen after CPAP therapy  Healio

Patients with obstructive sleep apnea syndrome who underwent continuous positive airway pressure therapy experienced an increase in choroidal thickness ...

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

First human test of robotic eye surgery a success  Medical Xpress

Researchers from the University of Oxford have completed the first successful trial of robot-assisted retinal surgery.

Clearside Biomedical: Buy Or Sell Before 2018 Catalysts  Seeking Alpha

The 8-week data from the first phase 3 trial (SAPPHIRE) in treating macular edema due to retinal vein occlusion is expected in Q4 (a big binary event for the st.

Lamellar macular hole surgery – current concepts, future prospects | OPTH  Dove Medical Press

Lamellar macular hole surgery - current concepts, future prospects Christos Haritoglou,1 Ramin Tadayoni,2 Jean-Pierre Hubschman3 1Herzog Carl Theodor ...

RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AI  PR Newswire

HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...

Topical timolol-dorzolamide combined with anti-VEGF could better treat macular edema  Healio

PHILADELPHIA – An ongoing study suggests that topical timolol-dorzolamide can reduce central subfield thickness in patients with persistent macular edema ...

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

Allergan plc (AGN) Reaches $138.98 After 7.00% Down Move; Nine Masts Capital LTD Has Decreased Lg Display Co LTD (LPL) Holding By $716,128  The FinHeadLines

The stock of Allergan plc (NYSE:AGN) is a huge mover today! The stock decreased 3.53% or $5.09 during the last trading session, reaching $138.98. About 1.24 ...

Habits You Need to Break to Protect Your Eyesight  Brit + Co

If you're reading this article with your very own eyes, take a moment to appreciate the way they're transmitting these wise words from your screen to your brain.

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

Therapy applied directly inside the eye best for treating uveitic macular edema  Medical Xpress

Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of ...

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN suffered a setback when the FDA issued a complete response letter (CRL) to its supplemental Biologics License.

» Load more